Coretherapix
WebCoretherapix S.L., a company incorporated and existing under the laws of Spain, having its registered office at Calle Xxxxxxxx Xxxxxxxx, 2 (Parque Xxxxxxxxxxx xx Xxxxxx) 00000 Xxxx Xxxxxx, Xxxxxx, Xxxxx and registered with the Commercial Registry of Madrid under volume number 24667, page 70, book 0, section 8 sheet M-443970 and with tax ... WebJul 30, 2015 · About Coretherapix Coretherapix, S.L. was founded in 2006 with the aim of developing effective and off-the-shelf products for the treatment of ischemic cardiac disease.
Coretherapix
Did you know?
WebJul 31, 2015 · Coretherapix, S.L. was founded in 2006 with the aim of developing effective and off-the-shelf products for the treatment of ischemic cardiac disease. Coretherapix's … WebAssignee: CORETHERAPIX SLU Inventors: Luis Rodriguez-Borlado, Itziar Palacios, José Luis Abad, Belén Sánchez, Virginia Álvarez, Rosalba Rosado ADULT CARDIAC STEM CELL POPULATION. Publication number: 20160030485 Abstract: The present invention relates to the identification, isolation, expansion and characterization of a specific type of ...
WebJul 30, 2015 · TiGenix (Euronext Brussels: TIG) on Thursday said it has acquired cell therapy company Coretherapix for 6.7 million euros ($1.3 million) in a cash and stock … WebSee Coretherapix funding rounds, investors, investments, exits and more. Evaluate their financials based on Coretherapix's post-money valuation and revenue. Coretherapix …
WebNov 23, 2009 · Coretherapix, however, is based on in-house research. The companies in Genetrix’ portfolio need support at nearly all levels of business, Márquez acknowledges. “They need to know about ... WebJul 30, 2015 · TiGenix acquires Coretherapix for an upfront payment of approximately €1.2M in cash and approximately €5.5M in new TiGenix shares. Additionally, Genetrix may receive up to €15M in new TiGenix shares depending on the results of the ongoing clinical trial of Coretherapix. Based on and subject to future sales milestones, Genetrix may …
WebApr 12, 2015 · The technological development core of the project, led by Coretherapix, was the advancement of a novel cardiac stem cell therapy (AlloCSC-01) through the preclinical validation stage, industrial manufacturing, regulatory approval and finally, the first-in-human clinical trial currently under way. In this collaborative effort, the project has ...
WebAcquisition expands buyer's cell therapy pipeline into cardiology treatments, led by the Phase II AlloCSC-01 for heart attack alete preDevelopment of myocardial reparative therapy for the treatment of acute ischemic cardiac disease, based on the intracoronary administration of allogeneic Cardiac Stem Cells (CSCs) to ameliorate myocardial cell death and promote cardio-regeneration. The study comprises two phases: Initial dose-escalation open-label safety phase comprising 6 ... alete logoWebCoretherapix S.L.U. (part of the Tigenix Group since July 2015, Madrid, Spain) sponsors the trial, which has been funded also by the European FP7-HEALTH-2009 program and by the Spanish Cardiovascular Research Network. The CAREMI trial is registered with the ClinicalTrials.gov identifier NCT 02439398. The authors and the sponsor are responsible ... alete dmWebDec 15, 2016 · TiGenix has raised a total of $69.1M in funding over 6 rounds. Their latest funding was raised on Nov 25, 2015 from a Private Equity round. TiGenix is registered under the ticker EBR:TIG . Their stock opened with $15.50 in its Dec 15, 2016 IPO. TiGenix is funded by 6 investors. Kreos Capital and NV Industriebank LIOF are the most recent … aleteia associazioneWebCoretherapix is a clinical stage company focused on developing cost effective regenerative therapies to stimulate the endogenous repair of the heart, and to prevent the negative … alete printingWebJul 30, 2015 · Coretherapix bases its cell therapy candidates on adult allogeneic cardiac progenitor/stem cells isolated from the right atrial appendages of donors, and expanded … aletea comunicacionWebCoretherapix General Information. Description. Manufacturer of pharmaceutical products. The company engages in manufacturing of AlloCSC-01 and regenerative therapies to … aleteia chapelet